"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
This article was originally published in The Pink Sheet Daily
Reference product payments could decline as proposed payment amounts would be a blend average sales price of the two products.
You may also be interested in...
The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23
Rep. Henry Waxman, D-Calif., can perhaps take some comfort in the fact that his defeat on follow-on biologics means his broader health reform legislation may have a greater chance of passage
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.